JP2025060958A5 - - Google Patents
Info
- Publication number
- JP2025060958A5 JP2025060958A5 JP2024232254A JP2024232254A JP2025060958A5 JP 2025060958 A5 JP2025060958 A5 JP 2025060958A5 JP 2024232254 A JP2024232254 A JP 2024232254A JP 2024232254 A JP2024232254 A JP 2024232254A JP 2025060958 A5 JP2025060958 A5 JP 2025060958A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- integrin
- rnai agent
- targeting ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663763P | 2018-04-27 | 2018-04-27 | |
| US62/663,763 | 2018-04-27 | ||
| US201962790372P | 2019-01-09 | 2019-01-09 | |
| US62/790,372 | 2019-01-09 | ||
| PCT/US2019/029393 WO2019210200A1 (en) | 2018-04-27 | 2019-04-26 | Integrin targeting ligands and uses thereof |
| JP2020560257A JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Division JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025060958A JP2025060958A (ja) | 2025-04-10 |
| JP2025060958A5 true JP2025060958A5 (cg-RX-API-DMAC10.html) | 2025-10-08 |
Family
ID=68294255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Active JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
| JP2024232254A Pending JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Active JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
Country Status (20)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309955A (en) | 2018-04-27 | 2024-03-01 | Arrowhead Pharmaceuticals Inc | Integrin-targeting ligands and their uses |
| KR20210113273A (ko) | 2019-01-09 | 2021-09-15 | 애로우헤드 파마슈티컬스 인코포레이티드 | HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법 |
| AU2021342155A1 (en) * | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
| EP4367246A4 (en) * | 2021-07-07 | 2026-07-29 | Alnylam Pharmaceuticals Inc | Integrin-targeting ligands for the ocular administration of arni compounds |
| CN121399119A (zh) * | 2023-06-19 | 2026-01-23 | 广东众生睿创生物科技有限公司 | 一种整合素配体及其用途 |
| WO2025252118A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州瑞博生物技术股份有限公司 | 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途 |
| WO2025261536A1 (zh) * | 2024-06-21 | 2025-12-26 | 长春金赛药业有限责任公司 | 一种整联蛋白配体关键中间体及其制备方法 |
| WO2026034639A1 (ja) * | 2024-08-09 | 2026-02-12 | 株式会社Spin Wave | ペプチド合成用可溶性担体およびこれを用いた合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| SK9192000A3 (en) * | 1997-12-17 | 2001-03-12 | Merck & Co Inc | Integrin receptor antagonists |
| AU2002337954C1 (en) | 2001-10-22 | 2008-10-23 | The Scripps Research Institute | Integrin targeting compounds |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| EP3673922A1 (en) * | 2008-03-14 | 2020-07-01 | VisEn Medical, Inc. | Integrin targeting agents and methods of using same |
| JP2012517447A (ja) | 2009-02-10 | 2012-08-02 | ザ スクリプス リサーチ インスティチュート | 化学的にプログラムされたワクチン接種法 |
| US9586916B2 (en) * | 2012-01-27 | 2017-03-07 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 |
| JP6383735B2 (ja) | 2013-01-28 | 2018-08-29 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Rsウイルスの抗ウイルス剤としてのキノキサリノンおよびジヒドロキノキサリノン |
| HK1214301A1 (zh) * | 2013-02-28 | 2016-07-22 | 箭头研究公司 | 治療epas1相關疾病的有機組合物 |
| WO2015021092A1 (en) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| EP3273965A4 (en) | 2015-03-26 | 2018-12-05 | Merck Sharp & Dohme Corp. | Composition and methods for treating chronic kidney disease |
| US11971402B2 (en) | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| JP2018514568A (ja) * | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
| TWI761305B (zh) | 2015-05-29 | 2022-04-21 | 美商愛羅海德製藥公司 | 抑制Hif2α基因表現之組合物及方法 |
| CN120247964A (zh) | 2018-02-17 | 2025-07-04 | 箭头药业股份有限公司 | 三炔连接剂和使用方法 |
| IL309955A (en) * | 2018-04-27 | 2024-03-01 | Arrowhead Pharmaceuticals Inc | Integrin-targeting ligands and their uses |
-
2019
- 2019-04-26 IL IL309955A patent/IL309955A/en unknown
- 2019-04-26 DK DK19794009.1T patent/DK3784269T3/da active
- 2019-04-26 US US17/050,042 patent/US12667619B2/en active Active
- 2019-04-26 ES ES19794009T patent/ES2983950T3/es active Active
- 2019-04-26 HR HRP20240907TT patent/HRP20240907T1/hr unknown
- 2019-04-26 WO PCT/US2019/029393 patent/WO2019210200A1/en not_active Ceased
- 2019-04-26 AU AU2019260738A patent/AU2019260738B2/en active Active
- 2019-04-26 KR KR1020207033772A patent/KR102787533B1/ko active Active
- 2019-04-26 BR BR112020021949-5A patent/BR112020021949A2/pt not_active Application Discontinuation
- 2019-04-26 EP EP24179088.0A patent/EP4435000A3/en active Pending
- 2019-04-26 IL IL278304A patent/IL278304B2/en unknown
- 2019-04-26 JP JP2020560257A patent/JP7704529B2/ja active Active
- 2019-04-26 CN CN201980028704.0A patent/CN112074290B/zh active Active
- 2019-04-26 SG SG11202009734VA patent/SG11202009734VA/en unknown
- 2019-04-26 JO JOP/2020/0266A patent/JOP20200266A1/ar unknown
- 2019-04-26 CA CA3097656A patent/CA3097656A1/en active Pending
- 2019-04-26 FI FIEP19794009.1T patent/FI3784269T3/fi active
- 2019-04-26 SI SI201930780T patent/SI3784269T1/sl unknown
- 2019-04-26 CN CN202411099363.5A patent/CN118994152A/zh active Pending
- 2019-04-26 EP EP19794009.1A patent/EP3784269B1/en active Active
- 2019-04-26 MX MX2020011290A patent/MX2020011290A/es unknown
- 2019-04-29 TW TW108114935A patent/TW202014206A/zh unknown
-
2020
- 2020-10-27 SA SA520420426A patent/SA520420426B1/ar unknown
-
2024
- 2024-12-27 JP JP2024232254A patent/JP2025060958A/ja active Pending